TCL Archive Von Eschenbach takes leave of absence from NCI, resigns from C-Change board. Acting FDA commissioner’s drug approval strategy rooted in unproven science. Von Eschenbach told NCI deputies he might drop in on meetings. Who’s really in charge? October 7, 2005
TCL Archive Analyzing Tumor Tissue In Clinical Trials Can Improve Outcomes, RTOG Trial Finds May 27, 2011
TCL Archive Early, Short Course Of Hormonal Therapy May Allow Patients To Live Longer January 25, 2008
TCL Archive In Brief: Increased Output Can Hold Down High Let Cost, Kligerman says; No More Groups On The Block March 18, 1977
